Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)
at www.tipranks.com (Tue, 30-Apr 7:52 AM)
at www.tipranks.com (Tue, 30-Apr 3:00 AM)
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
at www.tipranks.com (Fri, 26-Apr 8:35 AM)
at www.tipranks.com (Fri, 26-Apr 8:08 AM)
Scotiabank Remains a Buy on SAGE Therapeutics (SAGE)
at www.tipranks.com (Fri, 26-Apr 7:29 AM)
SAGE Therapeutics (SAGE) Receives a Hold from RBC Capital
at www.tipranks.com (Fri, 26-Apr 6:37 AM)
Sell Rating on Sage Therapeutics Amid Zurzuvae Sales Concerns and Pipeline Risks
at www.tipranks.com (Fri, 26-Apr 5:06 AM)
SAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
at www.tipranks.com (Fri, 26-Apr 2:21 AM)